百奥泰(688177.SH)：Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准

Core Viewpoint - The company Baiotai (688177.SH) has received marketing approval from the European Medicines Agency (EMA) for Gotenfia® (BAT2506), a drug indicated for multiple autoimmune conditions, which is expected to enhance the company's international market presence and positively impact long-term operational performance [1] Group 1: Product Approval - Gotenfia® is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis [1] - Gotenfia® is a TNF-α targeting antibody that binds specifically to soluble and membrane-bound human TNF-α, inhibiting its activity by blocking its interaction with the TNFR receptor [1] Group 2: Market Implications - The approval of Gotenfia® will further expand the company's international market and enhance the global influence of its products [1] - Existing competitors and potential new entrants may have first-mover advantages, indicating that Gotenfia® could face intense market competition in the future [1]